BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

1d ago, source:

(NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary ...

Q4 2023 BioCardia Inc Earnings Call

29d ago, source: Yahoo Finance

David McClung; Chief Financial Officer, Member of the Management Team; BioCardia Inc Brent Pearson George Hill Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome ...

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

1mon ago, source: Business Insider

SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

BioCardia Launches Pivotal CardiAMP HF II Trial

2mon ago, source: TipRanks on MSN

BioCardia Inc (BCDA) has released an update to notify the public and investors about a regulation fd disclosure. BioCardia, ...

BioCardia Inc.

8d ago, source: U.S. News & World Report

For most investors, the best investment strategy is to buy good stocks and hold them for the long run.

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

25d ago, source: Yahoo Finance

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript March 27, 2024 BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11. BCDA isn't one of the ...

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

1mon ago, source: Stockhouse

SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

BioCardia Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2023 Year-End Financial Results and Business Update Conference Call. At this time, all participants ...

BioCardia, Inc.: BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

1mon ago, source: Finanznachrichten

SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...